Investors and Media



Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins as novel therapeutics to treat unmet medical needs. We are worldwide leaders in developing zinc finger DNA-binding proteins (ZFPs) for therapeutic gene regulation and modification. Our ZFP technology platform has multiple applications in:

  • Human Therapeutics
  • High-value Research Tools
  • Transgenic Animals
  • Cell-line Engineering for Protein Manufacturing
  • Plant Agriculture

View all »   RSSRecent Releases

May 26, 2015
Sangamo BioSciences Announces Presentation At The Jefferies 2015 Global Healthcare Conference

May 18, 2015
Sangamo BioSciences Presents New Data from Proprietary ZFP Therapeutic Programs for Lysosomal Storge Disorders at Annual Meeting of the American Society of Gene and Cell Therapy


View all »Events & Presentations

Jun 1, 2015 at 1:30 PM ET
Jefferies 2015 Global Healthcare Conference

Jun 22, 2015 at 9:00 AM PT
2015 Annual Meeting of Stockholders

Stock Quote

Ticker:
SGMO
Exchange:
NASDAQ
Price:
12.46
Change:
+ 0.29
Day High:
12.52
Day Low:
12.02
Volume:
756,900
4:00 PM ET on May 26, 2015

Shareholder Tools